Paradigm Capital Management Inc. NY Boosts Stock Position in AngioDynamics, Inc. $ANGO

Paradigm Capital Management Inc. NY raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 5.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 718,200 shares of the medical instruments supplier’s stock after purchasing an additional 40,000 shares during the period. Paradigm Capital Management Inc. NY’s holdings in AngioDynamics were worth $8,166,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its position in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in AngioDynamics in the fourth quarter valued at $27,000. State of Wyoming acquired a new stake in AngioDynamics in the second quarter valued at $31,000. Russell Investments Group Ltd. boosted its stake in AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ANGO has been the subject of several recent analyst reports. HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Canaccord Genuity Group boosted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Price Performance

Shares of ANGO opened at $13.59 on Friday. The stock has a market capitalization of $561.67 million, a PE ratio of -15.62 and a beta of 0.34. The business’s fifty day moving average price is $12.53 and its 200 day moving average price is $11.39. AngioDynamics, Inc. has a 12-month low of $8.36 and a 12-month high of $15.19.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.